SDGRNasdaq

Schrodinger, Inc.

Healthcare·Oncology·Phase 1·New York, NY, United States
Oncology

Schrodinger, Inc. (SDGR): 3 pipeline candidates · ~84 mo cash runway. Updated within the last hour.

5.4/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway10.0

84.3 months

Financial Health6.9

D/E 1.02

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider Signal0.0

0 buys · 17 sells (180d)

A transparent, data-derived signal for Schrodinger, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$1.2B

Cash

$267.7M

Quarterly Burn

$14.8M

Runway

84.3 mo

Revenue

$58.6M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jun 2033
Today~93 mo out
Catalyst within runway

Pipeline (3 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

226

Total value held

$638.7M

HolderSharesValue
blackrock, inc.9,678,560$109.9M
gates foundation trust6,981,664$79.3M
vanguard capital management llc5,208,748$59.2M
vanguard portfolio management llc3,862,197$43.9M
amova asset management americas, inc.3,190,837$36.2M
massachusetts financial services co /ma/2,684,692$30.5M
state street corp2,191,427$24.9M
ark investment management llc2,067,135$23.5M
morgan stanley1,371,199$15.6M
geode capital management, llc1,351,496$15.4M

Showing top 10 of 226 institutional holders of Schrodinger, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Dr. Ramy Farid Ph.D.

Frequently asked questions

How many drug candidates are in Schrodinger, Inc.'s pipeline?

Schrodinger, Inc. (SDGR) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Schrodinger, Inc.'s lead drug candidate?

Schrodinger, Inc.'s most advanced tracked candidate is sgr-1505 (Phase 1) for relapsed or refractory B-cell lymphomas.

What is Schrodinger, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Schrodinger, Inc. has approximately 84.3 months of cash runway.

What is Schrodinger, Inc.'s market capitalization?

Schrodinger, Inc.'s market capitalization is approximately $1.2B.

Who is the CEO of Schrodinger, Inc.?

Dr. Ramy Farid Ph.D. is the chief executive officer of Schrodinger, Inc. (SDGR).

Get the full picture on Schrodinger, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.